SEC Form 4 · accession 0000886163-15-000036

LIGAND PHARMACEUTICALS INC · LGND

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — VP, Gen. Counsel & Secretary

Period of report

Mar 16, 2015

Accepted (ET)

Mar 18, 2015 · 4:32 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000886163

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Mar 16, 2015	S	6,000	$74.51	D	25,989	D
Common Stock	Mar 16, 2015	M	1,134	$14.47	A	27,123	D
Common Stock	Mar 16, 2015	S	1,134	$74.58	D	25,989	D
Common Stock	Mar 16, 2015	M	4,130	$21.92	A	30,119	D
Common Stock	Mar 16, 2015	S	4,130	$74.58	D	25,989	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F1	$14.47	Mar 16, 2015	M	1,134	D	—	Feb 9, 2022	Common Stock	1,134	0	D
Non-Qualified Stock Option (right to buy)^F2	$21.92	Mar 16, 2015	M	4,130	D	—	Feb 15, 2023	Common Stock	4,130	4,764	D

F1Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/09/12.
F2Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/15/13.